Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1995-06-06
1997-08-26
Nutter, Nathan M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514563, 514567, 560 19, A01N 3712, A01N 3744
Patent
active
056611790
ABSTRACT:
Compositions and methods of treating anemia, cancer, AIDS, or severe .beta.-chain hemoglobinopathies by administering a therapeutically effective amount of phenylacetate or pharmaceutically acceptable derivatives thereof or derivatives thereof alone or in combination or in conjunction with other therapeutic agents. Pharmacologically-acceptable salts alone or in combinations and methods of preventing AIDS and malignant conditions, and inducing cell differentiation are also aspects of this invention.
REFERENCES:
patent: 3973022 (1976-08-01), Goschke
patent: 3976673 (1976-08-01), Pifferi
patent: 3998966 (1976-12-01), Fried et al.
patent: 4028404 (1977-06-01), Bays et al.
patent: 4282214 (1981-08-01), Flora et al.
patent: 4457942 (1984-07-01), Brusilow
patent: 4470970 (1984-09-01), Burzynski
patent: 4702506 (1987-10-01), Munakata et al.
patent: 4720506 (1988-01-01), Munakata et al.
patent: 5244922 (1993-09-01), Burzynski
Neish "Phenylacetic Acid as a Potential Therapeutic Agent for the Treatment of Human Cancer" Experentia vol. 27:860-861 (1971).
Timothy J. Ley, et al., "5-Azacytidine Selectively Increases .gamma.-globin Synthesis in a Patient with .beta..sup.+ Thalassemia", New England Journal of Medicine, vol. 307:1469-1475 (Dec. 9, 1982).
Michael B. Sporn, et al., "Chemoprevention of Cancer with Retinoids", Federation Proceedings, vol. 38:2528-2534 (Oct. 1979).
Richard L. Momparler, et al., "Clinical Trial on 5-AZA-2'-Deoxycytidine in Patients with Acute Leukemia", Pharmac. Ther., vol. 30:277-286 (1985).
Gary J. Kelloff, et al., "Chemoprevention Clinical Trials", Mutation Research, vol. 267:291-295 (1992).
I. Bernard Weinstein, et al., "Cancer Prevention: Recent Progress and Future Opportunities", Cancer Research, vol. 51:5080s-5085s (1991).
Olli Simell, et al, "Waste Nitrogen Excretion Via Amino Acid Acylation: Benzoate and Phenylacetate in Lysinuric Protein Intolerance", Pediatr. Res., vol. 20:1117-1121 (1986).
Neish, et al., "Phenylacetic Acid as a Potential Therapeutic Agent for the Treatment of Human Cancer", Experentia, vol. 27:860-861 (1971).
J.A. Stamatoyannopoulos, et al., "Therapeutic Approaches to Hemoglobin Switching in Treatment of Hemoglobinopathies", Annu. Rev. Med., vol. 43:497-521 (1992).
Dvorit Samid, et al., "Selective Growth Arrest and Phenotypic Reversion of Prostate Cancer Cells In Vitro by NonToxic Pharmacological Concentrations of Phenylacetate", The Journal of Clinical Investigation, vol. 91:2288-2295 (1993).
Dvorit Samid, et al., "Induction of Erythroid Differentiation and Fetal Hemoglobin Production in Human Leukemic Cells Treated with Phenylacetate", Journal of the American Society of Hematology, vol. 80:1576-1581 (1992).
Dvorit Samid, et al., "Phenylacetate: A Novel Nontoxic Inducer of Tumor Cell Differentiation", Cancer Research, vol. 52:1988-1992 (1992).
George J. Dover, et al., "Increased Fetal Hemoglobin in Patients Receiving Sodium 4-Phenylbutyrate", The New England Journal of Medicine, vol. 327:569-570 (1992).
Burzynski, S.R. et al., Preclinical Studies on antineoplaston AS2-1 and Antineoplaston AS2-5, Drugs Exptl. Clin. Res.,Supplemental 1, XII:11-16 (1986).
Leary, Cancer Drug Also Helps in Treating Sickle Cell Anemia, Researchers Say, Atlanta Journal-Constitution, Thursday, Aug. 20, 1992.
Smigel, K., "Non-toxic drug being tested to treat cancer and anemias [news]", J. Natl. Cancer Inst., 84(18):1398 (Sep. 16, 1992).
Ross, Philip D. and Subramanian, S., Inhibition of sickle cell hemoglobin gelation by some aromatic compounds, Biochem. Biophys. Res. Commun., 77:1217-1223 (1977).
Jones, G.L., Anti sickling effects of Betw Di Ethylaminoethylidiphenylpropyl acetate SFK-525-A, Pharmacologist, 20(3):204 (1978).
Erhum, Wilson O., Acetonyl esters of hydroxybenzoic acids as potential antisickling agents, Niger. J. Pharm., 12:285-287 (1981).
Abemayor, E. et al., "Effects of retinoic acid on the in vivo growth of human neuroblastoma cells," Cancer Lett. (Netherlands), 55(1):1-5 (Nov. 19, 1990).
Cinatl, J. et al., In vitro differentiation of human neuroblastoma cells induced by sodium phenylacetate, Cancer Lett. (Netherlands), 70(1-2):15-24 (Jun. 15, 1993).
Gorski, G.K. et al., Synergistic inhibition of human rhabdomyosarcoma cells by sodium phenylacetate and tretinoin, In Vitro Cell. Dev. Biol., 29A:189-191 (Mar. 1993).
Shecter, Y. et al, "Hydroxyphenyl Acetate Derivatives Inhibit Protein Tyrosine Kinase Activity and Proliferation in Nb2 Rat Lymphoma Cells and Insulin-Induced Lipogenesis in Rat Adipocytes," Molecular and Cellular Endocrinology, vol. 80, pp. 183-192 (1991).
Samid, D. et al, "Interferon in Combinations with Antibioticgenic Phenyl Derivatives: Population of IFN a Activity In-Vitro," British J. Hematology, vol. 79 Supp. 1, pp. 81-83 (Oct. 10, 1991).
Nutter Nathan M.
The United States of America as represented by the Department of
LandOfFree
Methods for treating neoplastic conditions using phenylacetic ac does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating neoplastic conditions using phenylacetic ac, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating neoplastic conditions using phenylacetic ac will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1988916